Terms: = Endocrine gland cancer AND PR, PGR, progesterone receptor AND Clinical Outcome
35 results:
1. Targeting homologous recombination deficiency in uterine leiomyosarcoma.
Dall G; Vandenberg CJ; Nesic K; Ratnayake G; Zhu W; Vissers JHA; Bedő J; Penington J; Wakefield MJ; Kee D; Carmagnac A; Lim R; Shield-Artin K; Milesi B; Lobley A; Kyran EL; O'Grady E; Tram J; Zhou W; Nugawela D; Stewart KP; Caldwell R; Papadopoulos L; Ng AP; Dobrovic A; Fox SB; McNally O; Power JD; Meniawy T; Tan TH; Collins IM; Klein O; Barnett S; Olesen I; Hamilton A; Hofmann O; Grimmond S; Papenfuss AT; Scott CL; Barker HE
J Exp Clin Cancer Res; 2023 May; 42(1):112. PubMed ID: 37143137
[TBL] [Abstract] [Full Text] [Related]
2. PTEN Deficiency in Tubo-Ovarian High-Grade Serous Carcinoma is Associated with Poor Progression-Free Survival and is Mutually Exclusive with CCNE1 Amplification.
Zhang X; Wang A; Han L; Liang B; Allard G; Diver E; Howitt BE
Mod Pathol; 2023 May; 36(5):100106. PubMed ID: 36805789
[TBL] [Abstract] [Full Text] [Related]
3. clinical outcome and Treatment Sequences of Patients with Advanced Pancreatic cancer Treated with Contemporary Chemotherapy Protocols.
Roehrle J; Kasper S; Treckmann JW; Markus P; Schumacher B; Albers D; Wendling J; Ting S; Mende B; Maßmann M; Markus M; Virchow I; Rosery V; Laue K; Zaun G; Kostbade K; Pogorzelski M; Reissig TM; Liffers ST; Schmid K; Schildhaus HU; Schuler M; Siveke JT; Wiesweg M
Oncol Res Treat; 2023; 46(4):140-150. PubMed ID: 36720216
[TBL] [Abstract] [Full Text] [Related]
4. Positive
Huang S; Qi M; Tian T; Dai H; Tang Y; Huang R
Front Endocrinol (Lausanne); 2022; 13():959089. PubMed ID: 36407316
[TBL] [Abstract] [Full Text] [Related]
5. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Lee EK; Xiong N; Cheng SC; Barry WT; Penson RT; Konstantinopoulos PA; Hoffman MA; Horowitz N; Dizon DS; Stover EH; Wright AA; Campos SM; Krasner C; Morrissey S; Whalen C; Quinn R; Matulonis UA; Liu JF
Gynecol Oncol; 2020 Oct; 159(1):72-78. PubMed ID: 32771276
[TBL] [Abstract] [Full Text] [Related]
6. Progesteron receptor expression in insulin producing cells of neuroendocrine neoplasms.
Tachibana T; Kasajima A; Aoki T; Tabata T; McNamara K; Yazdani S; Satoko S; Fujishima F; Motoi F; Unno M; Sasano H
J Steroid Biochem Mol Biol; 2020 Jul; 201():105694. PubMed ID: 32437964
[TBL] [Abstract] [Full Text] [Related]
7. Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma.
Hollis RL; Stanley B; Iida Y; Thomson J; Churchman M; Rye T; Mackean M; Nussey F; Gourley C; Herrington CS
Gynecol Oncol; 2019 Nov; 155(2):318-323. PubMed ID: 31495455
[TBL] [Abstract] [Full Text] [Related]
8. The role of hepatic trans-arterial chemoembolization in metastatic medullary thyroid carcinoma: a specialist center experience and review of the literature.
Grozinsky-Glasberg S; Bloom AI; Lev-Cohain N; Klimov A; Besiso H; Gross DJ
Eur J Endocrinol; 2017 Apr; 176(4):463-470. PubMed ID: 28100632
[TBL] [Abstract] [Full Text] [Related]
9. Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: clinical outcomes and Preliminary Correlation with Biological Factors.
Spada F; Antonuzzo L; Marconcini R; Radice D; Antonuzzo A; Ricci S; Di Costanzo F; Fontana A; Gelsomino F; Luppi G; Nobili E; Galdy S; Cella CA; Sonzogni A; Pisa E; Barberis M; Fazio N
Neuroendocrinology; 2016; 103(6):806-14. PubMed ID: 26789262
[TBL] [Abstract] [Full Text] [Related]
10. progesterone receptor Isoforms A and B in Pancreatic Neuroendocrine Tumor.
Yazdani S; Kasajima A; Ogata H; Felizola SJ; Nakamura Y; Onodera Y; Watanabe M; Motoi F; Unno M; Sasano H
Neuroendocrinology; 2015; 101(4):309-20. PubMed ID: 25791399
[TBL] [Abstract] [Full Text] [Related]
11. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.
Matsuo K; Sheridan TB; Mabuchi S; Yoshino K; Hasegawa K; Studeman KD; Im DD; Rosenshein NB; Roman LD; Sood AK
Gynecol Oncol; 2014 Jun; 133(3):473-9. PubMed ID: 24674832
[TBL] [Abstract] [Full Text] [Related]
12. Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT.
Boers-Sonderen MJ; de Geus-Oei LF; Desar IM; van der Graaf WT; Oyen WJ; Ottevanger PB; van Herpen CM
Target Oncol; 2014 Dec; 9(4):339-47. PubMed ID: 24577626
[TBL] [Abstract] [Full Text] [Related]
13. Expression and prognostic significance of the polymeric immunoglobulin receptor in epithelial ovarian cancer.
Berntsson J; Lundgren S; Nodin B; Uhlén M; Gaber A; Jirström K
J Ovarian Res; 2014 Feb; 7():26. PubMed ID: 24568264
[TBL] [Abstract] [Full Text] [Related]
14. Impact of pregnancy on prognosis of differentiated thyroid cancer: clinical and molecular features.
Messuti I; Corvisieri S; Bardesono F; Rapa I; Giorcelli J; Pellerito R; Volante M; Orlandi F
Eur J Endocrinol; 2014 May; 170(5):659-66. PubMed ID: 24510913
[TBL] [Abstract] [Full Text] [Related]
15. Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports.
Suzuki S; Shibata K; Kikkawa F; Nakatsura T
Hum Vaccin Immunother; 2014; 10(2):338-43. PubMed ID: 24252799
[TBL] [Abstract] [Full Text] [Related]
16. Phenotypic characterization of hereditary epithelial ovarian cancer based on a tissue microarray study.
Muñoz-Repeto I; García MJ; Kamieniak M; Ramón Y Cajal T; Domingo S; Cazorla A; García Donas J; Hernando Polo S; García Sagredo JM; Hernández E; Lacambra C; Saez R; Robles L; Borrego S; Prat J; Palacios J; Benítez J
Histol Histopathol; 2013 Jan; 28(1):133-44. PubMed ID: 23233066
[TBL] [Abstract] [Full Text] [Related]
17. Immunohistochemical expression and prognostic significance of oestrogen receptor-alpha, oestrogen receptor-beta, and progesterone receptor in stage 1 adult-type granulosa cell tumour of the ovary.
Hutton SM; Webster LR; Nielsen S; Leung Y; Stewart CJ
Pathology; 2012 Dec; 44(7):611-6. PubMed ID: 23149378
[TBL] [Abstract] [Full Text] [Related]
18. PET/CT scanning guided intensity-modulated radiotherapy in treatment of recurrent ovarian cancer.
Du XL; Jiang T; Sheng XG; Li QS; Wang C; Yu H
Eur J Radiol; 2012 Nov; 81(11):3551-6. PubMed ID: 22521528
[TBL] [Abstract] [Full Text] [Related]
19. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients.
Odunsi K; Matsuzaki J; Karbach J; Neumann A; Mhawech-Fauceglia P; Miller A; Beck A; Morrison CD; Ritter G; Godoy H; Lele S; duPont N; Edwards R; Shrikant P; Old LJ; Gnjatic S; Jäger E
Proc Natl Acad Sci U S A; 2012 Apr; 109(15):5797-802. PubMed ID: 22454499
[TBL] [Abstract] [Full Text] [Related]
20. Expression of the proliferation marker Ki-67 associates with tumour staging and clinical outcome in differentiated thyroid carcinomas.
Müssig K; Wehrmann T; Dittmann H; Wehrmann M; Ueberberg B; Schulz S; Bares R; Petersenn S
Clin Endocrinol (Oxf); 2012 Jul; 77(1):139-45. PubMed ID: 22248072
[TBL] [Abstract] [Full Text] [Related]
[Next]
